{"id":"NCT01685437","sponsor":"Endo Pharmaceuticals","briefTitle":"A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease","officialTitle":"A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2012-09-14","resultsPosted":"2015-04-07","lastUpdate":"2017-10-05"},"enrollment":189,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Peyronie's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"AA4500","otherNames":["Xiaflex","Xiapex"]}],"arms":[{"label":"AA4500","type":"EXPERIMENTAL"}],"summary":"This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle. Enrollment will include all subjects who meet the eligibility criteria and who received placebo and completed one of the Auxilium-sponsored studies AUX-CC-803 or AUX-CC-804.","primaryOutcome":{"measure":"Percentage Change From Baseline in Penile Curvature","timeFrame":"Baseline and Week 36","effectByArm":[{"arm":"AA4500","deltaMin":-36.3,"sd":30.72}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":189},"commonTop":["Penile haematoma","Penile pain","Penile swelling","Penile oedema","Penile haemorrhage"]}}